

Review

## Roles of Calcium Regulating MicroRNAs in Cardiac Ischemia-Reperfusion Injury

Eunhyun Choi <sup>1,2</sup>, Min-Ji Cha <sup>1,2</sup>, and Ki-Chul Hwang <sup>1,2,\*</sup>

<sup>1</sup> Institute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangneung-si, Gangwon-do 210-701, Korea; E-Mails: ehchoi@ish.or.kr (E.C.); mjcha@yuhs.ac (M.-J.C.)

<sup>2</sup> Catholic Kwandong University International St. Mary's Hospital, Incheon Metropolitan City 404-834, Korea

\* Author to whom correspondence should be addressed; E-Mail: kchwang@cku.ac.kr or kchwang@ish.or.kr; Tel.: +82-32-290-3883.

Received: 26 May 2014; in revised form: 2 September 2014 / Accepted: 3 September 2014 /

Published: 11 September 2014

---

**Abstract:** Cardiac Ca<sup>2+</sup> cycling and signaling are closely associated with cardiac function. Changes in cellular Ca<sup>2+</sup> homeostasis may lead to aberrant cardiac rhythm and may play a critical role in the pathogenesis of cardiac diseases, due to their exacerbation of heart failure. MicroRNAs (miRNAs) play a key role in the regulation of gene expression at the post-transcriptional level and participate in regulating diverse biological processes. The emerging evidence indicates that the expression profiles of miRNAs vary among human diseases, including cardiovascular diseases. Cardiac Ca<sup>2+</sup>-handling and signaling proteins are also regulated by miRNAs. Given the relationship between cardiac Ca<sup>2+</sup> homeostasis and signaling and miRNA, Ca<sup>2+</sup>-related miRNAs may serve as therapeutic targets during the treatment of heart failure. In this review, we summarize the knowledge currently available regarding the role of Ca<sup>2+</sup> in cardiac function, as well as changes in Ca<sup>2+</sup> cycling and homeostasis and the handling of these processes by miRNAs during cardiac ischemia-reperfusion injury.

**Keywords:** microRNA; calcium; Ca<sup>2+</sup>; myocardial ischemia-reperfusion injury; heart

---

## 1. Introduction

Myocardial ischemia-reperfusion (I/R) injury is one of the leading causes of heart failure, and the signs and symptoms of I/R injury are characterized by an insufficient supply of oxygen and nutrients to the body; slowed, asynchronous contraction; and impaired relaxation of the heart muscle [1,2]. The key regulator of cardiac function is intracellular calcium ( $\text{Ca}^{2+}$ ), as  $\text{Ca}^{2+}$  acts as a second messenger and plays an important role in regulating cardiac physiology and pathophysiology. Altered expression and activity of  $\text{Ca}^{2+}$ -related proteins are associated with cardiac dysfunction, which is observed in many patients with heart failure [3,4].

Recently, endogenous small noncoding RNAs known as microRNAs (miRNAs) have been identified as novel regulators of gene expression at the post-transcriptional level and regulate several cellular processes, such as cell proliferation, differentiation, and apoptosis [5,6]. The biogenesis of miRNAs begin with primary miRNAs (pri-miRNAs), which transcribe miRNA gene by RNA polymerase II, and have hundreds to thousands of nucleotides and single or multiple stem-loop structures with a 5' cap and a poly(A) tail. The pri-miRNAs are cleaved by the microprocessor complex, composed of RNase-III endonuclease Drosha, RNA-binding protein (RBP) DGCR8, and other cofactors, which produce 70–100-nucleotide-long hairpin-shaped precursor miRNAs (pre-miRNAs). The pre-miRNAs are exported to the cytoplasm by the nuclear export protein exportin-5, and then they are finally trimmed by another RNase-III ribonuclease Dicer, generating a mature miRNA duplex that is approximately 21 nucleotides long. Finally, only one strand (a guide strand) of mature miRNA duplex is loaded to the RNA-induced silencing complex (RISC), whereas the other strand (the passenger strand) is degraded. The guide strand is the functional strand of the mature miRNAs and negatively regulates gene expression either by inhibiting mRNA translation or inducing mRNA degradation, which results from the complete or incomplete binding to the 3' untranslated region (3' UTR) of target mRNAs [7–10].


Recently, a number of miRNAs have been discovered; however a small portion of miRNAs are known to be expressed in the heart and an even smaller portion of miRNAs have been identified to be related to cardiac  $\text{Ca}^{2+}$  homeostasis [11]. Changes in the expression profiles of miRNAs are linked to several diseases, including cardiovascular disease, cancer, and diabetes [12–14]. Given the relationship between intracellular  $\text{Ca}^{2+}$  homeostasis and miRNAs during the regulation of cardiac function, the ability of miRNAs to regulate  $\text{Ca}^{2+}$ -handling proteins may be an important therapeutic target in the treatment of heart disease [1,14–16]. Among the heart-expressed miRNAs, in this review, we focused on miRNAs related to the intracellular  $\text{Ca}^{2+}$  homeostasis and  $\text{Ca}^{2+}$  regulation within myocardial I/R injury.

## 2. Role of Calcium in Cardiac Function

The maintenance of intracellular  $\text{Ca}^{2+}$  homeostasis in the heart is essential for many aspects of cardiac function, including cardiac excitation, contraction, and relaxation. Cardiac excitation-contraction coupling (EC-coupling) is associated with  $\text{Ca}^{2+}$ -induced  $\text{Ca}^{2+}$  release (CICR) [17]. Transmembrane and intracellular calcium channels and transporters participate in the movement of  $\text{Ca}^{2+}$ . Cardiac contraction is initiated by membrane depolarization, which leads to the activation of voltage-gated

L-type  $\text{Ca}^{2+}$  channels (LTCCs) and a subsequent increase in intracellular  $\text{Ca}^{2+}$  concentration due to the influx of extracellular  $\text{Ca}^{2+}$  [18]. This  $\text{Ca}^{2+}$  influx prompts a substantial release of  $\text{Ca}^{2+}$  from the sarcoplasmic reticulum (SR) into the cytoplasm through ryanodine receptor (RyR) channels. Cytosolic  $\text{Ca}^{2+}$  binds to  $\text{Ca}^{2+}$ -sensitive proteins, such as troponin, myosin, and actin, and subsequently initiates muscle contraction. During cardiac relaxation,  $\text{Ca}^{2+}$  is released from the myofilaments and pumped back into the SR via the SR  $\text{Ca}^{2+}$ -ATPase (SERCA2a) and is then transported to the extracellular space through the sarcolemmal  $\text{Na}^+/\text{Ca}^{2+}$  exchanger (NCX) [4,19].

**Figure 1.** Cardiac  $\text{Ca}^{2+}$ -handling and  $\text{Ca}^{2+}$ -mediated signaling. LTCC, L-type  $\text{Ca}^{2+}$  channel; NCX,  $\text{Na}^+/\text{Ca}^{2+}$  exchanger; CaM, calmodulin; CaMKII,  $\text{Ca}^{2+}$ /calmodulin-dependent protein kinase II; Cn, calcineurin; RyR2, ryanodine receptor type-2; SERCA2a, sarcoplasmic reticulum  $\text{Ca}^{2+}$ -ATPase; SR, sarcoplasmic reticulum; PLB, phospholamban; CICR,  $\text{Ca}^{2+}$ -induced  $\text{Ca}^{2+}$  release; MCU, mitochondrial  $\text{Ca}^{2+}$  uniporter; ANT, adenine nucleotide transporter; VDAC, voltage-dependent anion channel; TCA, tricarboxylic acid; OXPHOS, oxidative phosphorylation; HDAC, histone deacetylase; NFAT, nuclear factor of activated T-cells; MEF2, myocyte enhancer factor-2; P, phosphorylation.



Another important role of  $\text{Ca}^{2+}$  is the maintenance of cardiac cellular energy homeostasis. ATP is a key energy source in cardiac excitation and contraction, and the synthesis of ATP is tightly linked to oxidative phosphorylation in mitochondria [20,21]. The mitochondrial calcium uniporter (MCU) contributes to  $\text{Ca}^{2+}$  uptake in the mitochondria from the cytosol, which activates TCA cycle enzymes and then creates the electrochemical gradient. The TCA cycle generates electrons during the

conversion of NADH to NAD<sup>+</sup>, and these electrons are transferred through complexes I–IV of the electron transport chain (ETC). As a result of these processes, ATP is produced and released from the matrix of the mitochondrial inner membrane to the cytosol through two proteins, the adenine nucleotide transporter (ANT) on the mitochondrial inner membrane and the voltage-dependent anion channel (VDAC) on the mitochondrial outer membrane [3,22]. Therefore, cellular Ca<sup>2+</sup> homeostasis plays a critical role in regulating both cardiac function and mitochondrial ATP production (Figure 1).

### 3. MicroRNA Regulation of Calcium Signaling in Myocardial Ischemia-Reperfusion Injury


Recent research has demonstrated that miRNAs participate in cardiovascular development, function, and diseases. Several miRNAs either exert cardioprotective effects or play a role in the pathogenesis of diseases [23,24], and the expression profiles of miRNAs are dynamically different during various disease states [15,25,26]. Thus, the regulation of disease-mediated miRNAs is related to the pathophysiological mechanisms [27]. A number of miRNAs associated with cardiac I/R injury have been discovered; however, little is known regarding the detailed mechanisms by which they perform their functions. Nevertheless, miRNAs mediating cardiovascular disease, including I/R injury, have potential as therapeutic targets in disease management [28].

In this section, we focus on cardiac I/R injury, which is one of the leading causes of heart failure, cardiovascular disease, and sudden death, and provide a comprehensive summary of the changes in Ca<sup>2+</sup> cycling during cardiac I/R injury and the relationship between Ca<sup>2+</sup>-regulating miRNAs and cardiac function.

#### 3.1. Altered Ca<sup>2+</sup> Homeostasis During Cardiac Ischemia-Reperfusion Injury

Cardiac I/R injury is directly linked to cardiac dysfunction and results in an imbalance in Ca<sup>2+</sup> homeostasis [29,30]. I/R-injured cardiomyocytes are characterized by increased Ca<sup>2+</sup> concentrations in both the cytosol and the mitochondria, which are associated with abnormal cardiac function and damage to cardiac tissues [31,32]. During ischemia, a decrease in O<sub>2</sub> levels inhibits oxidative phosphorylation, which subsequently reduces ATP synthesis. The accumulation of lactate and the acceleration of acidification via anaerobic glycolysis inhibit the Na<sup>+</sup>/H<sup>+</sup> exchanger (NHE) and the Na<sup>+</sup>/K<sup>+</sup>-ATPase, which triggers Na<sup>+</sup> overload and a subsequent rise in Ca<sup>2+</sup> concentration in the cytosol via the NCX, as well as abnormal activity of the Ca<sup>2+</sup>-ATPase. In addition, the pH of the cytosol is acidic [33,34]. Paradoxically, reperfusion is necessary to enhance the functioning of the ischemic heart; however, it also exacerbates cardiac damage due to myocardial cell death [35]. During reperfusion, mitochondrial membrane potential ( $\Delta\Psi_m$ ) are rapidly reestablished, leading to uncoupling of oxidative phosphorylation and a sustained rise in Ca<sup>2+</sup> uptake into the mitochondria and the generation of reactive oxygen species (ROS). Ca<sup>2+</sup> and ROS, as well as the restoration of neutral pH in the cytosol, accelerate the opening of the mitochondrial permeability transition pore (mPTP), which subsequently results in a significant loss of ATP and causes mitochondria-mediated apoptosis [36,37] (Figure 2).

**Figure 2.** Cardiac Ca<sup>2+</sup> protein-regulated microRNA during ischemia-reperfusion injury. LTCC, L-type Ca<sup>2+</sup> channel; NCX, Na<sup>+</sup>/Ca<sup>2+</sup> exchanger; AnxA5, annexin A5; NHE, Na<sup>+</sup>/H<sup>+</sup> exchanger; CaM, calmodulin; CaMKII, Ca<sup>2+</sup>/calmodulin-dependent protein kinase II; RyR2, ryanodine receptor type-2; SERCA2a, sarcoplasmic reticulum Ca<sup>2+</sup>-ATPase; SR, sarcoplasmic reticulum; PLB, phospholamban; CICR, Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release; MCU, mitochondrial Ca<sup>2+</sup> uniporter; ROS, reactive oxygen species; CyP-D, cyclophilin D; mPTP, mitochondrial permeability transition pore; OXPHOS, oxidative phosphorylation; HDAC, histone deacetylase; P, phosphorylation.



### 3.2. MicroRNA Regulation of Ca<sup>2+</sup> Signaling During Cardiac Ischemia-Reperfusion Injury

Cardiac I/R injury leads to an increase in intracellular Ca<sup>2+</sup> concentration, and these Ca<sup>2+</sup> ions bind to and elevate the activity of calmodulin (CaM), which activates calcineurin (Cn), a downstream molecule of both CaM and Ca<sup>2+</sup>/calmodulin-dependent protein kinase II (CaMKII) [11,38]. Cn has phosphatase activity and dephosphorylates nuclear factor of activated T-cells (NFAT), which translocate into the nucleus from the cytosol and upregulate the expression of cardiac pathophysiology-related genes [4]. CaMKII is a serine/threonine-specific protein kinase and a critical regulator of Ca<sup>2+</sup> signaling that plays a role in cardiac disease [39,40]. Four CaMKII isoforms ( $\alpha$ ,  $\beta$ ,  $\gamma$ , and  $\delta$ ) have been identified and have different tissue distributions. In particular, CaMKII $\delta$  is the predominant isoform in the adult mammalian heart and has two splice variants, CaMKII $\delta_B$  and CaMKII $\delta_C$  [41]. CaMKII $\delta_B$  has an 11 amino-acid nuclear localization signal, which is absent in CaMKII $\delta_C$ ; therefore,

CaMKII $\delta_B$  localizes to the nucleus, whereas CaMKII $\delta_C$  localizes to the cytosol [42]. The histone deacetylase (HDAC) class II isoforms HDAC4 and HDAC5 are phosphorylated by activated CaMKII, which regulates myocyte enhancer factor-2 (MEF-2)-mediated cardiac hypertrophy-related gene expression [43,44].

Because of the importance of Ca<sup>2+</sup> in regulating proteins related to cardiac function and damage, the regulation of intracellular Ca<sup>2+</sup> is considered to be a therapeutic target [35]. Several strategies have been implemented to improve Ca<sup>2+</sup> regulation and to attenuate Ca<sup>2+</sup> overload. Phospholamban (PLB) is a major player in regulating SERCA2a activity; in addition, PLB activity is modulated by CaMKII. Dephosphorylation of PLB inhibits SERCA2a activity, thereby preventing Ca<sup>2+</sup> uptake in the SR. In this context, Shintani-Ishida *et al.* used calcineurin inhibitor cyclosporin A to prevent PLB dephosphorylation [45] and Gorbe *et al.* demonstrated that B-type natriuretic peptide (BNP) elevates PLB phosphorylation via the cGMP-dependent protein kinase (PKG) pathway [46]. In an I/R heart, CaMKII activity is increased; thus Vila-Petroff *et al.* investigated the cardioprotective effects of the CaMKII inhibitor KN-93 or the CaMKII inhibitory peptide AIP. In addition, KB-R7943, which inhibited the reverse mode NCX, showed outcomes similar to CaMKII inhibition [47]. To reduce Ca<sup>2+</sup> overload, Tani *et al.* suggested a contractile inhibitor using 2,3-butanedione monoxime (BDM) [48], and Dou *et al.* identified blebbistatin, a more powerful inhibitor of the actin–myosin interaction than BDM [49]. BDM and blebbistatin maintain a cardiac muscle contractile system, including cardiomyocyte and contraction inhibition and shortening. The loss of Ca<sup>2+</sup> homeostasis activates the non-lysosomal cysteine proteases calpains, which contribute to contractile dysfunction by impairing Ca<sup>2+</sup> regulation, and necrotic cell death. Therefore, calpain inhibitors promote cardioprotection against I/R injury; however, some calpain inhibitors, such as leupeptin, *N*-Ac-Leu-Leu-norleucinal (ALLN or calpain inhibitor I), and MDL-29170 (calpain inhibitor III) are unsuitable for *in vivo* applications due to poor aqueous solubility [50]. Improving the water solubility of calpain inhibitor A-705253 reduces the infarct size and improves left ventricular contractility in porcine I/R model [51]. However, the effectiveness of calpain inhibitors must be clearly confirmed in more clinically relevant animal models of human diseases, and calpain selectivity must be improved. Few clinical studies of Ca<sup>2+</sup> regulation have been performed, including (1) a study of nisoldipine, a vascular-selective organic calcium antagonist [52]; (2) the DATA trial with diltiazem, another calcium antagonist [53]; (3) the CASTEMI and EVLVE randomized trials using caldaret (MCC-135), an NCX inhibitor [54,55]; (4) studies using NHE inhibitors, such as the GUARDIAN or EXPEDITION studies of cariporide [56,57] and the ESCAMI trial with eniporide [58]; and (5) the J-WIND-ANP trial, which used either human atrial natriuretic peptide or nicorandil [59]. Unfortunately, the results of these clinical trials have been insignificant or have not proven the effectiveness of these inhibitors; thus, there is still a need to understand the mechanism behind the effects of cardiac Ca<sup>2+</sup> on cardiac function to develop more potent and selective modulators of Ca<sup>2+</sup>-related molecules.

Emerging evidence in the study of disease-related miRNAs has shown that changes in dynamic miRNA expression are linked to cardiac I/R injury, and Ca<sup>2+</sup> signaling molecules are also involved in changes in the expression of several miRNAs, as discussed in further detail below (Figure 2).

### 3.2.1. miR-25

Recently, Wahlquist *et al.* reported that miR-25 leads to an impairment in  $\text{Ca}^{2+}$  uptake and exacerbates heart failure by directly interacting with SERCA2a mRNA [60]. To identify the miRNAs that control SERCA2a, the authors constructed an eGFP-SERCA2a 3' UTR reporter vector to perform a high-content screen of 875 miRNAs and compared the results to those of SERCA2a siRNA (100% inhibition). The results of this experiment demonstrate that miR-25 is perhaps the most potent inhibitor of SERCA2a and is upregulated both in patients with severe heart failure and during trans-aortic constriction (TAC)-induced heart failure in a mouse model. Overexpression of miR-25 *in vivo* using adeno-associated virus 9 (AAV9) is related to declines in both fractional shortening and left ventricular (LV) function, whereas the inhibition of miR-25 with antagomiR reduces fibrosis and hypertrophy and improves cardiac contractility via the restoration of SERCA2a. Therefore, a strategy designed to inhibit miR-25 may be a key to developing a potential treatment for heart failure.

### 3.2.2. miR-1

MiR-1 is one of the best-characterized miRNAs in the heart, and has been linked to cardiac development, physiology, and pathophysiology, although studies of its function are still in progress [61–63]. In the I/R-injured heart, cardiac-enriched miR-1 exacerbates cardiac injury and apoptosis, whereas oligonucleotides modified to act against miR-1 (e.g., LNA-antimiR-1 or loss-of-function miR-1) attenuate I/R injury by restoring protein kinase C  $\epsilon$  (PKC $\epsilon$ ) and heat shock protein 60 (HSP60), which are targeted by miR-1 [64]. Both the overexpression and suppression of miR-1 have strong effects on  $\text{Ca}^{2+}$  flux in cardiomyocytes. The serum-response factor (SRF) regulates the transcription of NCX1 and miR-1. Tritsch *et al.* reported that the SRF/miR-1 axis regulates the expression of NCX1 and annexin A5 (AnxA5), a  $\text{Ca}^{2+}$ -binding protein that interacts with NCX1, and that miR-1 is directly suppressed by both NCX1 and AnxA5 [65]. Cardiomyocyte-specific tamoxifen-inducible inactivation of the SRF gene (SRF<sup>HK0</sup>) results in downregulation of NCX1 mRNA and primary miR-1 expression, but the translation of both NCX1 and AnxA5 is upregulated due to the downregulation of mature miR-1. Ultimately, the upregulation of NCX1 and AnxA5 restricts intracellular  $\text{Ca}^{2+}$  extrusion during heart failure.

Ali *et al.* suggested that miR-1 had an indispensable role in cardiac contractility, in which tamoxifen-induced cardiac-specific Dicer knockout mice demonstrated a significant decrease of miR-1 expression among the examined cardiac-specific miRNAs [66]. Decreases in miR-1 are correlated with increases in Sorcin, which resides on RyR2 and is a modulator of both calcium signaling and EC-coupling. Overexpression of Sorcin leads to dysregulation of  $\text{Ca}^{2+}$  signaling and deterioration of cardiac function under conditions of cardiomyopathy, whereas the siRNA-mediated knockout of Sorcin leads to the recovery of cardiac contractility in cardiac-specific Dicer knockout mice.

The PP2A regulatory subunit B56 $\alpha$  is another target of miR-1 and miR-133, and the inhibition of PP2A's function via miR-1 overexpression induces hyperphosphorylation and activation of RyR2, which subsequently promotes  $\text{Ca}^{2+}$  release from the SR, leading to abnormal  $\text{Ca}^{2+}$  cycling, and increased cardiac arrhythmogenesis [67,68].

### 3.2.3. miR-145

Increases in intracellular  $\text{Ca}^{2+}$  concentration are closely associated with the activation of CaMKII $\delta$ , which upregulates the expression of apoptotic genes. Cha *et al.* determined that miR-145 inhibits  $\text{Ca}^{2+}$  overload and  $\text{Ca}^{2+}$ -related signals by targeting CaMKII $\delta$ , and the overexpression of miR-145 protects against ROS-induced cardiomyocyte apoptosis [69].

### 3.2.4. miR-214

MiR-214 protects cardiomyocytes susceptible to cardiac I/R injury and heart failure and is upregulated in a variety of cardiac disease models [70]. Aurora *et al.* discovered a potential role of miR-214 in I/R injury. The heart-specific miR-214 knockout mice demonstrates that heart structure, size, and function are not significantly affected by the mutation, but  $\text{Ca}^{2+}$  regulator genes are upregulated compared to wild type mice. Additionally, miR-214 knockout mice exhibit more severe cardiac injury, including a greater extent of cardiomyocyte loss, larger fibrotic regions, and impaired cardiac performance compared to wild type mice according to a left anterior descending coronary artery (LAD) model [71]. The primary  $\text{Ca}^{2+}$  pump NCX1, a proapoptotic Bcl2 family protein known as BIM, CaMKII $\delta$ , and cyclophilin D (a major regulator of mPTP) are direct targets of miR-214. Cardiomyocytes from miR-214 knockout mice show both high levels of intracellular  $\text{Ca}^{2+}$  and  $\text{Ca}^{2+}$  overload. Therefore, miR-214 regulates  $\text{Ca}^{2+}$  homeostasis, and prevents cardiomyocyte death and protects against cardiac I/R injury by inhibiting the expression of the  $\text{Ca}^{2+}$ -handling molecule NCX1, as well as CaMKII $\delta$ , BIM, and cyclophilin D.

### 3.2.5. miR-494

MiR-494 is one of the miRNA transcripts that is downregulated in human infarcted and murine I/R-injured heart [11]. Wang *et al.* demonstrated that cardiac-specific overexpression of miR-494 in transgenic mice heart improves the recovery of cardiac function, reduces myocardial infarction size and prevents apoptosis by targeting the proapoptotic proteins PTEN, ROCK1, and CaMKII $\delta$ , as well as antiapoptotic proteins FGFR2 and LIF, and via the subsequent activation of AKT signaling in mitochondria [72].

### 3.2.6. miR-574-3p

In the infarcted myocardium, both the expression and function of SERCA2 are reduced, thereby inhibiting  $\text{Ca}^{2+}$  reuptake into the SR and subsequent  $\text{Ca}^{2+}$  overload, and the expression profiles of miRNAs are altered. The results of microarray and bioinformatics analyses demonstrate that miR-574-3p, which is upregulated in the area of myocardial infarcted, is a putative candidate miRNA that targets SERCA2a, but the authors suggest that further study (as opposed to immediate retesting) is necessary to confirm the relationship between miR-574-3p and SERCA2a [73].



### 3.2.7. miRNAs Related to Cardiomyocyte Cell Death: miR-15, miR-21, and miR-144/451 Cluster

MiR-15a/b are increased in the mice I/R injury model, and the inhibition of miR-15 (anti-miR-15 LNA) protects cardiomyocytes from hypoxia-induced cell death [74,75]. In addition, miR-21 is sensitive to ROS and protects against I/R-induced cardiac cell death by targeting programmed cell death 4 (PDCD4) [76]. The expression of the miR-144/451 cluster is regulated by GATA-4, a critical transcription factor in the heart, and the miR-144/451 cluster protects against I/R-induced cardiomyocyte apoptosis [77].

### 3.3. Circulating MicroRNAs as New Biomarkers

Circulating disease-mediated miRNAs are new biomarkers and therapeutic targets in the treatment of cardiovascular diseases [78,79]. The release mechanism, the causes of secretion and the altered expression profiles of the circulating miRNAs are still unknown. Some evidence suggests that circulating miRNAs may be released extracellularly, assisted by lipid vesicles such as exosomes, microvesicles, or apoptotic bodies that guard miRNAs against degradation by RNases [80,81]. During the I/R injury, plasma levels of miR-1, miR-133a, miR-499-5p, and cardiac-specific miR-208b rapidly increase in both rodent models and in human patients presenting with ST-elevation myocardial infarction (STEMI). In addition, circulating miR-1, miR-133a, miR-328, miR-499, and miR-208b levels also increase in patients who present with acute myocardial infarction [82,83]. Circulating miRNAs are attractive diagnostic biomarker; however, because of the low levels of miRNAs in the blood, it is necessary to develop reliable detection and analysis methods. However, the study of circulating disease-related miRNAs enables the development of the next generation of potent biomarkers and the early diagnosis and treatment of many diseases [81].

## 4. Conclusions

Recent research has provided increasing evidence that miRNAs are an important regulator of cardiac contractility and diseases, which are processes that are mediated by  $\text{Ca}^{2+}$  cycling abnormalities. Given the importance of cellular  $\text{Ca}^{2+}$  homeostasis and signaling in cardiac function and pathogenesis, a relatively small set of only a few  $\text{Ca}^{2+}$ -handling miRNAs have been discovered. In addition, clinical trials of cardiac disease-related miRNAs have not yet been initiated. Further research is necessary and may help us to identify new miRNAs that serve as potent therapeutic targets treating I/R-injured heart, allowing the elucidation of more detailed mechanisms of the role of miRNA- $\text{Ca}^{2+}$ -related proteins and genes in cardiac physiology and pathophysiology. These study results should facilitate more appropriate clinical trials to confirm the therapeutic function of miRNAs and the development of new drugs to treat cardiovascular diseases.

## Acknowledgments

This research was supported by a Korea Science and Engineering Foundation grant funded by the Korean government (MEST) (2014030459) and a grant from the Korea Health 21 R&D Project, Ministry of Health & Welfare, Korea (A120478).

## Author Contributions

E. Choi and M.-J. Cha wrote the manuscript; K.-C. Hwang supervised the writing and helped with editing.

## Conflicts of Interest

The authors declare no conflicts of interest.

## References

1. Luo, M.; Anderson, M.E. Mechanisms of altered Ca<sup>2+</sup> handling in heart failure. *Circ. Res.* **2013**, *113*, 690–708.
2. Buja, L.M. Myocardial ischemia and reperfusion injury. *Cardiovasc. Pathol.* **2005**, *14*, 170–175.
3. Viola, H.M.; Hool, L.C. How does calcium regulate mitochondrial energetics in the heart?—New insights. *Heart Lung Circ.* **2014**, *23*, 602–609.
4. Kho, C.; Lee, A.; Hajjar, R.J. Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy. *Nat. Rev. Cardiol.* **2012**, *9*, 717–733.
5. Peterson, S.M.; Thompson, J.A.; Ufkin, M.L.; Sathyanarayana, P.; Liaw, L.; Congdon, C.B. Common features of microRNA target prediction tools. *Front. Genet.* **2014**, *5*, 23.
6. Choi, E.; Choi, E.; Hwang, K.C. MicroRNAs as novel regulators of stem cell fate. *World J. Stem Cell.* **2013**, *5*, 172–187.
7. Macfarlane, L.A.; Murphy, P.R. MicroRNA: Biogenesis, function and role in cancer. *Curr. Genom.* **2010**, *11*, 537–561.
8. Elramah, S.; Landry, M.; Favereaux, A. MicroRNAs regulate neuronal plasticity and are involved in pain mechanisms. *Front. Cell. Neurosci.* **2014**, *8*, doi: 10.3389/fncel.2014.00031.
9. Di Leva, G.; Garofalo, M.; Croce, C.M. MicroRNAs in cancer. *Annu. Rev. Pathol.* **2014**, *9*, 287–314.
10. Winter, J.; Jung, S.; Keller, S.; Gregory, R.I.; Diederichs, S. Many roads to maturity: MicroRNA biogenesis pathways and their regulation. *Nat. Cell Biol.* **2009**, *11*, 228–234.
11. Harada, M.; Luo, X.; Murohara, T.; Yang, B.; Dobrev, D.; Nattel, S. MicroRNA regulation and cardiac calcium signaling: Role in cardiac disease and therapeutic potential. *Circ. Res.* **2014**, *114*, 689–705.
12. Aghabozorg Afjeh, S.S.; Ghaderian, S.M. The role of microRNAs in cardiovascular disease. *Int. J. Mol. Cell. Med.* **2013**, *2*, 50–57.
13. Ling, H.; Fabbri, M.; Calin, G.A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. *Nat. Rev. Drug Discov.* **2013**, *12*, 847–865.
14. Vickers, K.C.; Rye, K.A.; Tabet, F. MicroRNAs in the onset and development of cardiovascular disease. *Clin. Sci.* **2014**, *126*, 183–194.
15. Zhou, S.; Liu, Y.; Prater, K.; Zheng, Y.; Cai, L. Roles of microRNAs in pressure overload- and ischemia-related myocardial remodeling. *Life Sci.* **2013**, *93*, 855–862.
16. Aronsen, J.M.; Swift, F.; Sejersted, O.M. Cardiac sodium transport and excitation-contraction coupling. *J. Mol. Cell. Cardiol.* **2013**, *61*, 11–19.
17. Bers, D.M. Cardiac excitation-contraction coupling. *Nature* **2002**, *415*, 198–205.

18. Bodi, I.; Mikala, G.; Koch, S.E.; Akhter, S.A.; Schwartz, A. The L-type calcium channel in the heart: The beat goes on. *J. Clin. Invest.* **2005**, *115*, 3306–3317.
19. Katz, A.M.; Lorell, B.H. Regulation of cardiac contraction and relaxation. *Circulation* **2000**, *102*, 69–74.
20. Balaban, R.S. Cardiac energy metabolism homeostasis: Role of cytosolic calcium. *J. Mol. Cell. Cardiol.* **2002**, *34*, 1259–1271.
21. Glancy, B.; Balaban, R.S. Role of mitochondrial  $\text{Ca}^{2+}$  in the regulation of cellular energetics. *Biochemistry* **2012**, *51*, 2959–2973.
22. Tarasov, A.I.; Griffiths, E.J.; Rutter, G.A. Regulation of ATP production by mitochondrial  $\text{Ca}^{2+}$ . *Cell Calcium* **2012**, *52*, 28–35.
23. Porrello, E.R. Micromnas in cardiac development and regeneration. *Clin. Sci.* **2013**, *125*, 151–166.
24. Condorelli, G.; Latronico, M.V.; Cavarretta, E. Micromnas in cardiovascular diseases: Current knowledge and the road ahead. *J. Am. Coll. Cardiol.* **2014**, *63*, 2177–2187.
25. Weiss, J.B.; Eisenhardt, S.U.; Stark, G.B.; Bode, C.; Moser, M.; Grundmann, S. MicroRNAs in ischemia-reperfusion injury. *Am. J. Cardiovasc. Dis.* **2012**, *2*, 237–247.
26. Ye, Y.; Perez-Polo, J.R.; Qian, J.; Birnbaum, Y. The role of microRNA in modulating myocardial ischemia-reperfusion injury. *Physiol. Genom.* **2011**, *43*, 534–542.
27. Gladka, M.M.; da Costa Martins, P.A.; de Windt, L.J. Small changes can make a big difference - microRNA regulation of cardiac hypertrophy. *J. Mol. Cell. Cardiol.* **2012**, *52*, 74–82.
28. Dorn, G.W., Jr. Therapeutic potential of microRNAs in heart failure. *Curr. Cardiol. Rep.* **2010**, *12*, 209–215.
29. Shintani-Ishida, K.; Inui, M.; Yoshida, K. Ischemia-reperfusion induces myocardial infarction through mitochondrial  $\text{Ca}^{2+}$  overload. *J. Mol. Cell. Cardiol.* **2012**, *53*, 233–239.
30. Kalogeris, T.; Baines, C.P.; Krenz, M.; Korthuis, R.J. Cell biology of ischemia/reperfusion injury. *Int. Rev. Cell Mol. Biol.* **2012**, *298*, 229–317.
31. Griffiths, E.J. Mitochondria and heart disease. *Adv. Exp. Med. Biol.* **2012**, *942*, 249–267.
32. Walters, A.M.; Porter, G.A., Jr.; Brookes, P.S. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. *Circul. Res.* **2012**, *111*, 1222–1236.
33. Mozaffari, M.S.; Liu, J.Y.; Abebe, W.; Baban, B. Mechanisms of load dependency of myocardial ischemia reperfusion injury. *Am. J. Cardiovasc. Dis.* **2013**, *3*, 180–196.
34. Kadenbach, B.; Ramzan, R.; Moosdorf, R.; Vogt, S. The role of mitochondrial membrane potential in ischemic heart failure. *Mitochondrion* **2011**, *11*, 700–706.
35. Garcia-Dorado, D.; Ruiz-Meana, M.; Inserte, J.; Rodriguez-Sinovas, A.; Piper, H.M. Calcium-mediated cell death during myocardial reperfusion. *Cardiovasc. Res.* **2012**, *94*, 168–180.
36. Webster, K.A. Mitochondrial membrane permeabilization and cell death during myocardial infarction: Roles of calcium and reactive oxygen species. *Fut. Cardiol.* **2012**, *8*, 863–884.
37. Ong, S.B.; Gustafsson, A.B. New roles for mitochondria in cell death in the reperfused myocardium. *Cardiovasc. Res.* **2012**, *94*, 190–196.
38. Swaminathan, P.D.; Purohit, A.; Hund, T.J.; Anderson, M.E. Calmodulin-dependent protein kinase ii: Linking heart failure and arrhythmias. *Circ. Res.* **2012**, *110*, 1661–1677.

39. Westenbrink, B.D.; Edwards, A.G.; McCulloch, A.D.; Brown, J.H. The promise of camkii inhibition for heart disease: Preventing heart failure and arrhythmias. *Expert Opin. Ther. Tar.* **2013**, *17*, 889–903.
40. Anderson, M.E. Camkii and a failing strategy for growth in heart. *J. Clin. Invest.* **2009**, *119*, 1082–1085.
41. Anderson, M.E.; Brown, J.H.; Bers, D.M. Camkii in myocardial hypertrophy and heart failure. *J. Mol. Cell. Cardiol.* **2011**, *51*, 468–473.
42. Zhang, T.; Brown, J.H. Role of Ca<sup>2+</sup>/calmodulin-dependent protein kinase II in cardiac hypertrophy and heart failure. *Cardiovasc. Res.* **2004**, *63*, 476–486.
43. Backs, J.; Song, K.; Bezprozvannaya, S.; Chang, S.; Olson, E.N. Cam kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. *J. Clin. Invest.* **2006**, *116*, 1853–1864.
44. Zhang, T.; Kohlhaas, M.; Backs, J.; Mishra, S.; Phillips, W.; Dybkova, N.; Chang, S.; Ling, H.; Bers, D.M.; Maier, L.S.; *et al.* Camkiidelta isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. *J. Biol. Chem.* **2007**, *282*, 35078–35087.
45. Shintani-Ishida, K.; Yoshida, K. Ischemia induces phospholamban dephosphorylation via activation of calcineurin, PKC-alpha, and protein phosphatase 1, thereby inducing calcium overload in reperfusion. *Biochim. Biophys. Acta* **2011**, *1812*, 743–751.
46. Gorbe, A.; Giricz, Z.; Szunyog, A.; Csont, T.; Burley, D.S.; Baxter, G.F.; Ferdinandy, P. Role of CGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation. *Basic Res. Cardiol.* **2010**, *105*, 643–650.
47. Vila-Petroff, M.; Salas, M.A.; Said, M.; Valverde, C.A.; Sapia, L.; Portiansky, E.; Hajjar, R.J.; Kranias, E.G.; Mundina-Weilenmann, C.; Mattiazzi, A. Camkii inhibition protects against necrosis and apoptosis in irreversible ischemia-reperfusion injury. *Cardiovasc. Res.* **2007**, *73*, 689–698.
48. Tani, M.; Hasegawa, H.; Suganuma, Y.; Shinmura, K.; Kayashi, Y.; Nakamura, Y. Protection of ischemic myocardium by inhibition of contracture in isolated rat heart. *Am. J. Physiol.* **1996**, *271*, H2515–H2519.
49. Dou, Y.; Arlock, P.; Arner, A. Blebbistatin specifically inhibits actin-myosin interaction in mouse cardiac muscle. *Am. J. Physiol. Cell Physiol.* **2007**, *293*, C1148–C1153.
50. Inserte, J.; Hernando, V.; Garcia-Dorado, D. Contribution of calpains to myocardial ischaemia/reperfusion injury. *Cardiovasc. Res.* **2012**, *96*, 23–31.
51. Khalil, P.N.; Neuhof, C.; Huss, R.; Pollhammer, M.; Khalil, M.N.; Neuhof, H.; Fritz, H.; Siebeck, M. Calpain inhibition reduces infarct size and improves global hemodynamics and left ventricular contractility in a porcine myocardial ischemia/reperfusion model. *Eur. J. Pharmacol.* **2005**, *528*, 124–131.
52. Sheiban, I.; Tonni, S.; Chizzoni, A.; Marini, A.; Trevi, G. Recovery of left ventricular function following early reperfusion in acute myocardial infarction: A potential role for the calcium antagonist nisoldipine. *Cardiovasc. Drugs Ther.* **1997**, *11*, 5–16.
53. Theroux, P.; Gregoire, J.; Chin, C.; Pelletier, G.; de Guise, P.; Juneau, M. Intravenous diltiazem in acute myocardial infarction. Diltiazem as adjunctive therapy to activase (data) trial. *J. Am. Coll. Cardiol.* **1998**, *32*, 620–628.

54. Bar, F.W.; Tzivoni, D.; Dirksen, M.T.; Fernandez-Ortiz, A.; Heyndrickx, G.R.; Brachmann, J.; Reiber, J.H.; Avasthy, N.; Tatsuno, J.; Davies, M.; *et al.* Results of the first clinical study of adjunctive caldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: The randomized multicentre castemi study. *Eur. Heart J.* **2006**, *27*, 2516–2523.
55. Jang, I.K.; Weissman, N.J.; Picard, M.H.; Zile, M.R.; Pettigrew, V.; Shen, S.; Tatsuno, J.; Hibberd, M.G.; Tzivoni, D.; Wackers, F.J.; *et al.* A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (evolve). *Am. Heart J.* **2008**, *155*, 113.e1–113.e8.
56. Theroux, P.; Chaitman, B.R.; Danchin, N.; Erhardt, L.; Meinertz, T.; Schroeder, J.S.; Tognoni, G.; White, H.D.; Willerson, J.T.; Jessel, A. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the guardian trial. Guard during ischemia against necrosis (guardian) investigators. *Circulation* **2000**, *102*, 3032–3038.
57. Mentzer, R.M., Jr.; Bartels, C.; Bolli, R.; Boyce, S.; Buckberg, G.D.; Chaitman, B.; Haverich, A.; Knight, J.; Menasche, P.; Myers, M.L.; *et al.* Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: Results of the expedition study. *Ann. Thorac. Surg.* **2008**, *85*, 1261–1270.
58. Zeymer, U.; Suryapranata, H.; Monassier, J.P.; Opolski, G.; Davies, J.; Rasmanis, G.; Linszen, G.; Tebbe, U.; Schroder, R.; Tiemann, R.; *et al.* The Na<sup>+</sup>/H<sup>+</sup> exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (escami) trial. *J. Am. Coll. Cardiol.* **2001**, *38*, 1644–1650.
59. Kitakaze, M.; Asakura, M.; Kim, J.; Shintani, Y.; Asanuma, H.; Hamasaki, T.; Seguchi, O.; Myoishi, M.; Minamino, T.; Ohara, T.; *et al.* Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Two randomised trials. *Lancet* **2007**, *370*, 1483–1493.
60. Wahlquist, C.; Jeong, D.; Rojas-Munoz, A.; Kho, C.; Lee, A.; Mitsuyama, S.; van Mil, A.; Park, W.J.; Sluijter, J.P.; Doevendans, P.A.; *et al.* Inhibition of miR-25 improves cardiac contractility in the failing heart. *Nature* **2014**, *508*, 531–535.
61. Wystub, K.; Besser, J.; Bachmann, A.; Boettger, T.; Braun, T. miR-1/133a clusters cooperatively specify the cardiomyogenic lineage by adjustment of myocardin levels during embryonic heart development. *PLoS Genet.* **2013**, *9*, e1003793.
62. Curcio, A.; Torella, D.; Iaconetti, C.; Pasceri, E.; Sabatino, J.; Sorrentino, S.; Giampa, S.; Micieli, M.; Polimeni, A.; Henning, B.J.; *et al.* MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts. *PLoS ONE* **2013**, *8*, e70158.
63. Shan, H.; Zhang, Y.; Cai, B.; Chen, X.; Fan, Y.; Yang, L.; Chen, X.; Liang, H.; Zhang, Y.; Song, X.; *et al.* Upregulation of microRNA-1 and microRNA-133 contributes to arsenic-induced cardiac electrical remodeling. *Int. J. Cardiol.* **2013**, *167*, 2798–2805.

64. Pan, Z.; Sun, X.; Ren, J.; Li, X.; Gao, X.; Lu, C.; Zhang, Y.; Sun, H.; Wang, Y.; Wang, H.; *et al.* miR-1 exacerbates cardiac ischemia-reperfusion injury in mouse models. *PloS One* **2012**, *7*, e50515.
65. Tritsch, E.; Mallat, Y.; Lefebvre, F.; Diguët, N.; Escoubet, B.; Blanc, J.; De Windt, L.J.; Catalucci, D.; Vandecasteele, G.; Li, Z.; *et al.* An SRF/miR-1 axis regulates NCX1 and annexin A5 protein levels in the normal and failing heart. *Cardiovasc. Res.* **2013**, *98*, 372–380.
66. Ali, R.; Huang, Y.; Maher, S.E.; Kim, R.W.; Giordano, F.J.; Tellides, G.; Geirsson, A. miR-1 mediated suppression of sorcin regulates myocardial contractility through modulation of Ca<sup>2+</sup> signaling. *J. Mol. Cell. Cardiol.* **2012**, *52*, 1027–1037.
67. Terentyev, D.; Belevych, A.E.; Terentyeva, R.; Martin, M.M.; Malana, G.E.; Kuhn, D.E.; Abdellatif, M.; Feldman, D.S.; Elton, T.S.; Gyorke, S. miR-1 overexpression enhances Ca<sup>2+</sup> release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit b56alpha and causing camkii-dependent hyperphosphorylation of RyR2. *Circ. Res.* **2009**, *104*, 514–521.
68. Belevych, A.E.; Sansom, S.E.; Terentyeva, R.; Ho, H.T.; Nishijima, Y.; Martin, M.M.; Jindal, H.K.; Rochira, J.A.; Kunitomo, Y.; Abdellatif, M.; *et al.* MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. *PloS One* **2011**, *6*, e28324.
69. Cha, M.J.; Jang, J.K.; Ham, O.; Song, B.W.; Lee, S.Y.; Lee, C.Y.; Park, J.H.; Lee, J.; Seo, H.H.; Choi, E.; *et al.* MicroRNA-145 suppresses ros-induced Ca<sup>2+</sup> overload of cardiomyocytes by targeting camkiidelta. *Biochem. Biophys. Res. Commun.* **2013**, *435*, 720–726.
70. Van Rooij, E.; Sutherland, L.B.; Liu, N.; Williams, A.H.; McAnally, J.; Gerard, R.D.; Richardson, J.A.; Olson, E.N. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 18255–18260.
71. Aurora, A.B.; Mahmoud, A.I.; Luo, X.; Johnson, B.A.; van Rooij, E.; Matsuzaki, S.; Humphries, K.M.; Hill, J.A.; Bassel-Duby, R.; Sadek, H.A.; *et al.* MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca<sup>2+</sup> overload and cell death. *J. Clin. Invest.* **2012**, *122*, 1222–1232.
72. Wang, X.; Zhang, X.; Ren, X.P.; Chen, J.; Liu, H.; Yang, J.; Medvedovic, M.; Hu, Z.; Fan, G.C. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. *Circulation* **2010**, *122*, 1308–1318.
73. Bostjancic, E.; Zidar, N.; Glavac, D. MicroRNAs and cardiac sarcoplasmic reticulum calcium ATPase-2 in human myocardial infarction: Expression and bioinformatic analysis. *BMC Genomics* **2012**, *13*, 552.
74. Liu, L.F.; Liang, Z.; Lv, Z.R.; Liu, X.H.; Bai, J.; Chen, J.; Chen, C.; Wang, Y. MicroRNA-15a/b are up-regulated in response to myocardial ischemia/reperfusion injury. *J. Geriatr. Cardiol.* **2012**, *9*, 28–32.
75. Hullinger, T.G.; Montgomery, R.L.; Seto, A.G.; Dickinson, B.A.; Semus, H.M.; Lynch, J.M.; Dalby, C.M.; Robinson, K.; Stack, C.; Latimer, P.A.; *et al.* Inhibition of miR-15 protects against cardiac ischemic injury. *Circ. Res.* **2012**, *110*, 71–81.
76. Cheng, Y.; Liu, X.; Zhang, S.; Lin, Y.; Yang, J.; Zhang, C. MicroRNA-21 protects against the H<sub>2</sub>O<sub>2</sub>-induced injury on cardiac myocytes via its target gene PDCD4. *J. Mol. Cell. Cardiol.* **2009**, *47*, 5–14.

77. Zhang, X.; Wang, X.; Zhu, H.; Zhu, C.; Wang, Y.; Pu, W.T.; Jegga, A.G.; Fan, G.C. Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. *J. Mol. Cell. Cardiol.* **2010**, *49*, 841–850.
78. Salic, K.; De Windt, L.J. Micronas as biomarkers for myocardial infarction. *Curr. Atherosclerosis Rep.* **2012**, *14*, 193–200.
79. Reid, G.; Kirschner, M.B.; van Zandwijk, N. Circulating micrnas: Association with disease and potential use as biomarkers. *Crit. Rev. Oncol. Hematol.* **2011**, *80*, 193–208.
80. Pegtel, D.M.; Cosmopoulos, K.; Thorley-Lawson, D.A.; van Eijndhoven, M.A.; Hopmans, E.S.; Lindenberg, J.L.; de Gruijl, T.D.; Wurdinger, T.; Middeldorp, J.M. Functional delivery of viral mirnas via exosomes. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 6328–6333.
81. Creemers, E.E.; Tijssen, A.J.; Pinto, Y.M. Circulating micrnas: Novel biomarkers and extracellular communicators in cardiovascular disease? *Circ. Res.* **2012**, *110*, 483–495.
82. Kuwabara, Y.; Ono, K.; Horie, T.; Nishi, H.; Nagao, K.; Kinoshita, M.; Watanabe, S.; Baba, O.; Kojima, Y.; Shizuta, S.; *et al.* Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. *Circ. Cardiovasc. Genet.* **2011**, *4*, 446–454.
83. Adachi, T.; Nakanishi, M.; Otsuka, Y.; Nishimura, K.; Hirokawa, G.; Goto, Y.; Nonogi, H.; Iwai, N. Plasma microrna 499 as a biomarker of acute myocardial infarction. *Clin. Chem.* **2010**, *56*, 1183–1185.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).